We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Technique Catalogs Lymphoma-Linked Genetic Variations

By LabMedica International staff writers
Posted on 17 Jan 2013
A novel approach has been devised to sort out random mutations in genes associated with lymphoma, and the proteins produced by the genes could be tested to see how they performed. More...


Antigen receptor signaling to nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB), is essential for normal lymphocyte activation, but is dysregulated in several types of lymphoma.

Scientists at Johns Hopkins School of Medicine (Baltimore, MD, USA) made copies of the caspase recruitment domain family, member 11 (CARD11) gene in a way that made random mutations likely. The CARD11 protein plays a key role in signaling the presence of infection, which leads infection-fighting white blood cells to grow and divide.

The investigators then used the faulty copies to make mutant proteins, and tested the ability of those proteins to trigger the signaling reaction that is CARD11's specialty. This allowed them to find to which mutations increased the protein's activity and by how much and this information could then be compared to emerging data about CARD11 mutations found in human lymphomas. They noted that CARD11 is part of the NF- κB signaling pathway, a target of some cancer therapies
.
Joel Pomerantz, PhD, an associate professor in the Johns Hopkins School of Medicine's Institute for Cell Engineering, and senior author of the study said "Our goal was to correlate various mutations with potential to promote lymphoma. We imagine eventually being able to correlate response to a particular therapy with a particular mutation." The cancers called lymphomas, affect about 75,000 patients in the United States of America each year. The study was published in the January 2013 issue of the journal Molecular and Cellular Biology.

Related Links:

Johns Hopkins School of Medicine




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.